

For Immediate Release

CyGenics' T-cell Clinical Trials

4th FEBRUARY 2005 – Leading stem cell biotechnology and immunotherapy company, CyGenics, Ltd. (ASX: CYN) announced that it has been in detailed communications with the US Food & Drug Administration (FDA), on its Phase I/II clinical trials, using T-cells produced in its T-cell growth platform, to restore the damaged immune systems of patients.

The Investigational New Drug Application (IND) filing, made on 21st November 2004, underwent the customary initial review by the FDA. The FDA has requested for additional information beyond what is currently available to be included for review. CyGenics expects that it will require 6-8 months to furnish this information. In addition, a review of the trial design for the Phase I/II study has led to a proposed reduction in the number of patients required for the study. This reduction in the number of patients required may reduce the necessary duration of the trial by 3-6 months.

CyGenics has in the meanwhile completed the technology transfer to its clinical trials partners, Cell Therapies Pty Ltd and the Peter MacCallum Cancer Centre in Melbourne Australia. Over the course of the next 6-8 months, Cell Therapies and the Peter Mac will begin technical dry runs to fully test the procedures and processes required for these trials.



The target patient group for these clinical trials will be patients with haematologic malignancies and reduced T lymphocyte counts as a result of treatment. Under the protocol, blood stem cells and skin cells will be extracted from the patients, and grown in the scaffold to produce new T-cells that will be transfused back into the patients. A successful completion of these trials will place CyGenics among the first in the world to offer safe, efficacious and cost effective means of producing T-cells for therapeutic uses, addressing a key limitation in the treatment of patients whose immune systems have been damaged.

About CyGenics

CyGenics is a biotechnology and immunotherapy company focused on the development and commercialisation of stem cell-related products, services, applications and technologies. From its headquarters in Australia, CyGenics operates three divisions: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), and Cytomatrix (cell therapeutics and technology development) based in the USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com.

For more information, please contact:

Ronald Hee	Rod Nockles
Corporate Communications & Marketing Manager	Director
CordLife Pte Ltd	Financial & Corporate Relations
600 North Bridge Road,	Level 20,
#12-09/10, Parkview Square,	114 William Street
Singapore 188778, Singapore	Melbourne Victoria 3000
	Australia
Tel : +65 6238 0808	Tel: +61 3 9670 7996
Fax : +65 6295 1108	Fax: +61 3 9670 3883
Mobile: +65 9061 9098	Mobile: +61 (0) 419 691 323
Email: rhee@cordlife.com	E-mail: r.nockles@fcr.com.au